Heart failure & cardiomyopathiesCohort study

Optimizing Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Through Integrated Care Strategies

JACC AdvPublication date not resolved

  • prospective, observational study
  • propensity-matched
  • matched win-ratio

Authors' conclusion

A multidisciplinary approach combining dietary counseling, remote monitoring, and potassium binders was associated with improved optimization of MRA therapy in HFrEF patients at risk of hyperkalemia. This model may offer potential clinical benefit and underscores the value of team-based care in HF management.

Study context

Population
Patients with HFrEF at risk of hyperkalemiaafter 1:1 propensity matching, 82 pairs · exposure 51 · Medly 134
Participants
185 patients
Exposure
Structured mineralocorticoid receptor antagonist (MRA) titration vs propensity-matched cohort followed on Medly
  • exposuren = 51
  • Medlyn = 134reference

Main finding

As reported in the abstract

Baseline potassium · baseline

P < 0.001

Observational data: associations, not effects.

Further findings

Use of potassium binders · higher in exposure group

P < 0.001

OutcomeHR (95% CI)P value
MRA optimization rates · higher with exposure4.67 (1.93–11.27)P < 0.001
Outcomewin ratio (95% CI)P value
Composite win ratio (death, HF hospitalization, LVEF improvement, hyperkalemic events) · favored the exposure group · matched win-ratio2.5 (1.3–6.35)P = 0.005
OutcomeEstimateP value
HF hospitalizations · fewer with exposureP = 0.014
  • MRA optimization rates: after 1:1 propensity matching (82 pairs)
  • Heart failure (HF) hospitalizations: after 1:1 propensity matching (82 pairs)

Original publication

Optimizing Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Through Integrated Care Strategies. JACC Adv. doi:10.1016/j.jacadv.2026.102845

Summarised from the published abstract; every number is checked against it